SAN FRANCISCO, March 13, 2017 /PRNewswire/ -- Symic Bio, a biopharmaceutical company focused on matrix biology that is developing a new category of therapeutics, today announced that Rinko Ghosh, President and Chief Business Officer, will present an overview of current programs at the upcoming 11th Annual BIO-Europe Spring Conference.
Conference details are as follows:
Date: Tuesday, March 21, 2017
Time: 11:45 a.m. CET
Location: CCIB Convention Centre, Barcelona, Spain
About Symic Bio
Symic Bio is a biopharmaceutical company focused on matrix biology that is developing a new category of therapeutics. These therapeutics, with potential applications in a wide variety of disease states, are inspired by naturally occurring macromolecules that play key regulatory roles within the extracellular matrix. Symic Bio currently has two clinical candidates: SB-030, which will initially target the prevention of peripheral vein graft failure and SB-061, directed at disease modification and pain management in the treatment of osteoarthritis. In addition, Symic Bio is investigating applications in the areas of fibrosis, oncology and diseases of the central nervous system. For additional information please visit the company's website at www.symic.bio, LinkedIn page at www.linkedin.com/company/symic-bio or follow on Twitter at www.twitter.com/symicbio.
Gitanjali Jain Ogawa
The Trout Group
SOURCE Symic Bio